{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:39:08Z","timestamp":1786120748185,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023A1515012401"],"award-info":[{"award-number":["2023A1515012401"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012401"],"award-info":[{"award-number":["2023A1515012401"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16238-1","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:05:15Z","timestamp":1780481115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia"],"prefix":"10.1186","volume":"26","author":[{"given":"Yun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"2","key":"16238_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3.","journal-title":"Blood Cancer J"},{"issue":"11","key":"16238_CR2","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/leu.2016.126","volume":"30","author":"VI Gaidzik","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2160\u20138. https:\/\/doi.org\/10.1038\/leu.2016.126.","journal-title":"Leukemia"},{"issue":"10393","key":"16238_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, et al. Acute myeloid leukaemia[J]. Lancet. 2023;401(10393):2073\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3.","journal-title":"Lancet"},{"issue":"19","key":"16238_CR4","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1182\/blood-2011-12-397091","volume":"119","author":"H Guo","year":"2012","unstructured":"Guo H, Ma O, Speck NA, et al. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis[J]. Blood. 2012;119(19):4408\u201318. https:\/\/doi.org\/10.1182\/blood-2011-12-397091.","journal-title":"Blood"},{"issue":"3","key":"16238_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1182\/bloodadvances.2018024422","volume":"3","author":"M Gerritsen","year":"2019","unstructured":"Gerritsen M, Yi G, Tijchon E, et al. RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs[J]. Blood Adv. 2019;3(3):320\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2018024422.","journal-title":"Blood Adv"},{"issue":"2","key":"16238_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.14348\/molcells.2019.0252","volume":"43","author":"A Yokota","year":"2020","unstructured":"Yokota A, Huo L, Lan F, et al. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies[J]. Mol Cells. 2020;43(2):145\u201352. https:\/\/doi.org\/10.14348\/molcells.2019.0252.","journal-title":"Mol Cells"},{"issue":"15","key":"16238_CR7","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","volume":"129","author":"R Sood","year":"2017","unstructured":"Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies[J]. Blood. 2017;129(15):2070\u201382. https:\/\/doi.org\/10.1182\/blood-2016-10-687830.","journal-title":"Blood"},{"issue":"15","key":"16238_CR8","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2016-12-689109","volume":"129","author":"M de Bruijn","year":"2017","unstructured":"de Bruijn M, Dzierzak E. Runx transcription factors in the development and function of the definitive hematopoietic system[J]. Blood. 2017;129(15):2061\u20139. https:\/\/doi.org\/10.1182\/blood-2016-12-689109.","journal-title":"Blood"},{"issue":"2","key":"16238_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/leu.2011.202","volume":"26","author":"Y Satoh","year":"2012","unstructured":"Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells[J]. Leukemia. 2012;26(2):303\u201311. https:\/\/doi.org\/10.1038\/leu.2011.202.","journal-title":"Leukemia"},{"issue":"6","key":"16238_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2014-06-585513","volume":"125","author":"I Antony-Debre","year":"2015","unstructured":"Antony-Debre I, Manchev VT, Balayn N, et al. Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia[J]. Blood. 2015;125(6):930\u201340. https:\/\/doi.org\/10.1182\/blood-2014-06-585513.","journal-title":"Blood"},{"issue":"1","key":"16238_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","volume":"6","author":"S Wakita","year":"2022","unstructured":"Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia[J]. Blood Adv. 2022;6(1):238\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2021004292.","journal-title":"Blood Adv"},{"issue":"5","key":"16238_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41375-022-01548-7","volume":"36","author":"Y Hayashi","year":"2022","unstructured":"Hayashi Y, Harada Y, Harada H. Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective[J]. Leukemia. 2022;36(5):1203\u201314. https:\/\/doi.org\/10.1038\/s41375-022-01548-7.","journal-title":"Leukemia"},{"key":"16238_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-5-46","volume":"5","author":"L Xuan","year":"2012","unstructured":"Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies[J]. J Hematol Oncol. 2012;5:46. https:\/\/doi.org\/10.1186\/1756-8722-5-46.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"16238_CR14","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Haematol. 2023;10(8):e600\u201311. https:\/\/doi.org\/10.1016\/S2352-3026(23)00117-5.","journal-title":"Lancet Haematol"},{"issue":"1","key":"16238_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/ajh.70116","volume":"101","author":"TJ Kirtek","year":"2026","unstructured":"Kirtek TJ, Chen W, Harris JC, et al. Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group[J]. Am J Hematol. 2026;101(1):70\u20138. https:\/\/doi.org\/10.1002\/ajh.70116.","journal-title":"Am J Hematol"},{"issue":"1","key":"16238_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/16078454.2020.1765561","volume":"25","author":"K Wang","year":"2020","unstructured":"Wang K, Zhou F, Cai X, et al. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation[J]. Hematology. 2020;25(1):211\u20138. https:\/\/doi.org\/10.1080\/16078454.2020.1765561.","journal-title":"Hematology"},{"issue":"8","key":"16238_CR17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia[J]. Cancer Cell. 2022;40(8):850\u201364. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002.","journal-title":"Cancer Cell"},{"issue":"24","key":"16238_CR18","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1158\/0008-5472.CAN-17-0319","volume":"77","author":"D Speidel","year":"2017","unstructured":"Speidel D, Wellbrock J, Abas M. RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis[J]. Cancer Res. 2017;77(24):6818\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0319.","journal-title":"Cancer Res"},{"issue":"12","key":"16238_CR19","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","volume":"36","author":"NJ Short","year":"2022","unstructured":"Short NJ, Fu C, Berry DA, et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis[J]. Leukemia. 2022;36(12):2817\u201326. https:\/\/doi.org\/10.1038\/s41375-022-01692-0.","journal-title":"Leukemia"},{"issue":"10","key":"16238_CR20","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary Management of Acute Myeloid Leukemia: A Review[J]. JAMA Oncol. 2024;10(10):1417\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2662.","journal-title":"JAMA Oncol"},{"issue":"2","key":"16238_CR21","doi-asserted-by":"publisher","first-page":"e3256","DOI":"10.1002\/hon.3256","volume":"42","author":"LY Wang","year":"2024","unstructured":"Wang LY, Li Y, Jiang Q, et al. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis[J]. Hematol Oncol. 2024;42(2):e3256. https:\/\/doi.org\/10.1002\/hon.3256.","journal-title":"Hematol Oncol"},{"issue":"10","key":"16238_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41409-021-01322-w","volume":"56","author":"J Waidhauser","year":"2021","unstructured":"Waidhauser J, Labopin M, Esteve J, et al. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT[J]. Bone Marrow Transpl. 2021;56(10):2445\u201353. https:\/\/doi.org\/10.1038\/s41409-021-01322-w.","journal-title":"Bone Marrow Transpl"},{"key":"16238_CR23","doi-asserted-by":"publisher","unstructured":"Ran WJ, Xu LP, Zhang XH, et al. Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation[J]. Curr Oncol. 2025;32(6). https:\/\/doi.org\/10.3390\/curroncol32060294.","DOI":"10.3390\/curroncol32060294"},{"key":"16238_CR24","doi-asserted-by":"publisher","first-page":"107483","DOI":"10.1016\/j.leukres.2024.107483","volume":"139","author":"CL Wan","year":"2024","unstructured":"Wan CL, Huang YH, Huang SM, et al. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study[J]. Leuk Res. 2024;139:107483. https:\/\/doi.org\/10.1016\/j.leukres.2024.107483.","journal-title":"Leuk Res"},{"issue":"12","key":"16238_CR25","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.26724","volume":"97","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, DiNardo CD, Loghavi S, et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia[J]. Am J Hematol. 2022;97(12):1560\u20137. https:\/\/doi.org\/10.1002\/ajh.26724.","journal-title":"Am J Hematol"},{"issue":"6","key":"16238_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2[J]. Blood. 2022;139(6):907\u201321. https:\/\/doi.org\/10.1182\/blood.2021013156.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16238-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:43:24Z","timestamp":1786063404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16238-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16238"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16238-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (Approval Number: NFEC-2025-505), and it has been reviewed and approved by the Chinese Clinical Trial Registry (Registration number: ChiCTR2500111148) and registered in the National Medical Research Information Filing Information System of China. All patient information obtained was collected with the patients\u2019 informed consent. All experiments were performed in accordance with relevant laws, guidelines and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"940"}}